For instance, the QuANTUM-First trial demonstrated significantly prolonged OS with quizartinib plus chemotherapy compared to placebo (31.9 vs. 15.1 months, p = 0.032) in newly diagnosed FLT3-ITD AML [44]. Here, FLT3 is linked to acute myeloid leukemia.